carglumic acid

Size: px
Start display at page:

Download "carglumic acid"

Transcription

1

2 carglumic acid

3

4 carglumic acid (rinn)

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23 JueI VC, Massey lr,l. Myasthenia gravis. Orphanet J Rare Dis Nov 6i2:44. Leonardi M, Raggi A, Antozzi C, Confalonieri P, Maggi L, et al. The relationship between health, disability and quality of life in Myasthenia Gravis: results from an Italian study. J Neurol Jani257: doi /s Epub 2009 Aug 8. Matsuda M, Dohi-lijima N, Nakamura A, et al. Increase in incidence of elderly onset patients with myasthenia gravis in Nagano Prefecture, Japan. Intern Medicine Jun, 44 (a):stz-1. Murai H, Yamashita N, Watanabe M, Nomura Y, et al. Characteristics of nyasthenia gravis according to onset-age: Japanese nationwide survey. J Neurol Sci. 20tl Jun 15; 305(l-2) i doi: /j. jns.20lt epub2ol1 Nlar 26. Okinaka S, Reese HH, Katsuki S, et al. The prevalence of multiple sclerosis and other neurological diseases in Japan. 1966,47 (Suppl l9): Romi F, Gilhus NE, AarIi Jn. Myasthenia gravis: clinical, immunological, and therapeutic advances. Acta Neurol Scand Feb; 111(2):134-4I.

24

25

26

27

28

29

30 AUCo-e (ng'tu,/nn-)

31

32

33

34

35

36

37

38

39 I lq!e+ti

40

41 87

42

43

44

45

46

47

48 ):, I -, *rjrjn-,

49

50 6 2tL7 7

51 9.7 a?/1r ) r1qlonl

52

53

54

55

56

57

58

59

60 t24 'oe 1- I

61

62

63

64

65

66

67 Co (nc/ml)

68 s(+)l+ifvu (mllmrn) X (nglml)

69 tttto 7) sc/i,!$fij (300rgl E tfl) *5$offiH*o

70 copies/ml- =too,ooo Sloo,ooo copies/ml-

71

72

73

74

75

76 $mso 54 6mg 75 6mg D--? > = l--/v 36.0mg 2 Omg 27mg Q connoo"orr

77 028 mg'/ml 7Omg 0.28 mg,/ml ntg,/ ml ng,/ml 50mg /:4 7 tv 047 mg,/ml l4{ mg,/ml mg'/ml mg'/ml mg,/ml Q comomtrt

78 177ev >y 4C7Y> 7 -= l-y' 7+tt / t t> )l tv ts-v P e> Q Comornurt

79 C Codrd.tr{.1

80 0 { 3 r? r 3 { 5 6 I 3 9lr1rr, 0 a 12 $ an 31 *+t9i:1+t) &+B i=ir a+gsi_t r+ui I l3e_xlzbrrf,9fofit+utel s4iqrri 6e t 1pj (hr) {64.46,78 4l) t06.61 (94.73, r l9 98) t 4 l.l9 (132 64, I 50 30) (7.97, t0.0t) t4.m ( r3.4q l5 45) t7.21 ( ) l.l + (094, 1.38) 1.53 (1.21,194) 22E u ) 0.62,1.76) t.l6 (1.13, I l9) ,200) z,t I u 99, 2.38) t , r 8l) 2.12 (2.46,3 0t) G csftd.nffit

81 AUCuz+r fue'tr,/rl\ C tn. (!s,,/ rj.\ c2451 (rs./ml \ AUCou +n, (ub'tu/nj,\ Crr fus'/nl]. c2g1 (ro./mr \ ll lr ( ) 2.4r fl.8.3.4) (L t74.29\ l8.39ll /L ',1 1.90! i \ t45.99 (l s6.53\ (L3t.t \ 25.96s 17.17r ( \ fi5.80. I \ 2.41! ( ) ( \ ( ) I 5.88! (L0.2s.24.60\ 3.01{ fl ) Q Cortactrat

82 Q cornootrr

83 Q Cornornu*

84

85 r: i? y 2 zl tv 0.75%

86 vt.y ) 7, )v0.75% 7 tv=-)v

87

88

89

90

91 *77aiE:fiil 5pg azyv>y *7Aaid:fril 20rrg arrury *A7oEHil 60ug 72rU>Y

92 I 5ue

93

94

95

96

97

98 t Elffi tt+tvz ito.lb ' il#tr, r\t tv2 No.2o t Elffi r\l.tvz No.2z o ilffi, tt+.tvz t{0.24

99 t'l ET tv=*tv N.N'-t 7 - =)V,t:, 7 - = V l,/ )7 :. >

100 x7:a- 1., ztrty]/z- /\1.,7- -79*yV=

101

102

103

104

105

106

107 -49,999,,\

108

109

110

111

112

2 (1) (2) SCI 2 SCI 2 24 2 12 2

2 (1) (2) SCI 2 SCI 2 24 2 12 2 2004 (1) (2) (2) (3) (1) 1 (2) (3) 2 (1) (2) SCI 2 SCI 2 24 2 12 2 100% / 16 2002 2003 http://lin.lin.go.jp/alic/month/dome/1997/nov/chousa.htm (05 612 1315 1618 1922 2329 3039 4049 5059 60 ) =10 b g 1

More information

2 / 7

2 / 7 1 / 7 1.30 1.301.00m 2.00 2.001.00m 1.70 1.701.00m 2.4 2.41.0m 2.0 2.01.0m 1.08 1.20.9m 1.08 1.20.9m 2.5 2.51.0m 2.5 2.51.0m 0.9 1.00.9m 1.44 1.60.9m 2 / 7 ml ml 3 / 7 4 / 7 ) 5 / 7 6 / 7 0798-56-1710

More information

fff,smg l?t)- fle5mg ---o--. 5 mg ----c- l0 mg +20 mg Cmu 6c/mL) 10mg 20mg (mean t SD) (nglml) ft! omm fij /mm lfi o.tg e triz [h] N-12 (23.0) (27.e) (2.00-6.00) I E 2 El AUC",""") C**,,, t*,,,0) trn,""

More information

スライド 1

スライド 1 1 2006 msv 2 2011 3 CT 2011 10mSv 10 40mSv 4 2012 217mSv 5 (CT) 2012 50 60mSv 6 2012 510mSv BRCA25 310 10mSv3% BRCA60-280% 3 5m Sv 1m Sv 12% . http://www.rea.or.jp/ire/pdf/report4.pdf 1.10 20 SMR 1.00

More information

NIHSS score p NIHSS score p149 4 p g ml 0.8 g ml D 1 D NIH NIHSS 14 D 0.8 g ml

NIHSS score p NIHSS score p149 4 p g ml 0.8 g ml D 1 D NIH NIHSS 14 D 0.8 g ml NIHSS score14 1 400 1 p149 1 25 20 NIHSS score14 15 10 5 2 p149 4 p151 0 0.8 g ml 0.8 g ml D 1 D NIH NIHSS 14 D 0.8 g ml 1 2 148 149 3 2 3 A B C 4 D 2 A B C A C 1 Ogata T et al J Neurol Sci 272 83 86 2008

More information

慢性膵炎

慢性膵炎 - - 121 , g CCK g g - kgkcal kgkcal - g,,, - G.I.Res ; 10 : - ; 13 : - ; 22 : - Meier RF, Beglinger C. Nutrition in pancreatic diseases. Best Pract Res Clin Gastroenterol ; 20 : - Pfutzer RH, Schneider

More information

Q E Q T a k Q Q Q T Q =

Q E Q T a k Q Q Q T Q = i 415 q q q q Q E Q T a k Q Q Q T Q = 10 30 j 19 25 22 E 23 R 9 i i V 25 60 1 20 1 18 59R1416R30 3018 1211931 30025R 10T1T 425R 11 50 101233 162 633315 22E1011 10T q 26T10T 12 3030 12 12 24 100 1E20 62

More information

求人面接資料PPT

求人面接資料PPT Hair Salon TV etc. 250" 250" 200" 200" 150" 150" 100" 100" 50" 50" 0" 0" Nov)13" Dec)13" Jan)14" Feb)14" Mar)14" Apr)14" May)14" Jun)14" Jul)14" Dec)12" Jan)13" Feb)13" Mar)13" Apr)13"

More information

14 35H-3 35H-3 15 b f f b b b f f f f f f f f f f b b f f f f f b b b b b b b b b f f f f f f f f f f f f f

14 35H-3 35H-3 15 b f f b b b f f f f f f f f f f b b f f f f f b b b b b b b b b f f f f f f f f f f f f f bff b b b ff ff ff f f ff b b ff ff f b b b b b b b b b f f f f f f f f f f f f f b b ï ñ ó ff ff ò ô ö ù û û Æ õ ú ü! bõ ú b μ b b b f f f f f f f f f f f f b b bõ fl fi f f f f f f f f b b b b@ b b ff

More information

et al No To Shinkei Clin Neurol Neurology et al J Neurosurg et al Arch Neurol et al Angiology

et al No To Shinkei Clin Neurol Neurology et al J Neurosurg et al Arch Neurol et al Angiology 37 Recommendations for the Management of Moyamoya Disease A Statement from Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) Research on intractable diseases of the

More information

21-07_後藤論文.smd

21-07_後藤論文.smd 2015; 21: 5866 Yoichi Goto: Current status and future perspective of cardiac rehabilitation in Japan. J Jpn Coron Assoc 2015; 21: 5866 I 1 1 3 1 2 3 QOL 2 Fig. 1 1 196070 AMI AMI 1980 AMI CABG comprehensive

More information

32 1 BRONJ BRONJ II BRONJ BRONJ 4 BP BRONJ 6 1 III BP BRONJ

32 1 BRONJ BRONJ II BRONJ BRONJ 4 BP BRONJ 6 1 III BP BRONJ 29 1 31 40 2014 31 Bisphosphonate related osteonecrosis of jaw; BRONJ 2008 4 2012 3 36 98 8 11 19 BRONJ 0 13 2 5 3 1 1 0 BP 4 15 10 5 α-streptococcus 0 BRONJ BRONJ BP I Paget 1 409-3898 1110 2014 1 27

More information

欧州に見るマイナス金利が銀行に及ぼす影響

欧州に見るマイナス金利が銀行に及ぼす影響 TEL 3-6733-17 E-mail 1 / 14 216 5 27 TEL 3-6733-17 E-mail 2 / 14 EU 2161 2146 2152 2127 2149 21412 2163 216 3.1%.1%...5%.6% 1.25%.65% CD.75%.5% 1.45% 1.2% 1 (2164 ).82%.97%.62%.51%.259% 3.325% 2161 1 6,4

More information

il E ------------= 5E 1B H 171819 l /\yl-.';t'.-/t rl -,1i* [ F,li*/L .7 F rli- r" )'> F,f.*)v 'u,, tv ,/tvz '/u, )v 7./:/, )v7 /7tvz t'//lv7 oebrft tt ''No,2R.4

More information

zrtt-^fi.-.zl, . i f.,t, -zl, +lv)t* v-,f,.- L,)l;f- L ,)ll'- L,a,v^ i>/,va 4/ tvz /'/ tvz t\/ 1-n Ef, (3) 4 551drtl }E--EE(2] 4-JZG. o luanrr i *0.5i 2oomi I T/iE] l 9/ t4 9/15 :r-r'87>

More information

2.2 緒言エクリズマブ エクリズマブ ソリリス点滴静注 300mg 第 2 部 CTD の概要 2.2 緒言 アレクシオンファーマ合同会社

2.2 緒言エクリズマブ エクリズマブ ソリリス点滴静注 300mg 第 2 部 CTD の概要 2.2 緒言 アレクシオンファーマ合同会社 エクリズマブ ソリリス点滴静注 300mg 第 2 部 CTD の概要 2.2 緒言 アレクシオンファーマ合同会社 目次 2.2 緒言... 3 2.2.1 参考文献... 5 頁 2 / 5 2.2 緒言 重症筋無力症 (MG) は 神経筋接合部 (NMJ) における自己抗体の結合による神経筋伝達異 常が原因で引き起こされる 稀な消耗性の後天性自己免疫性神経障害である こうした自己抗体は 神経伝達物質であるアセチルコリンによる筋への神経刺激伝達のために不可欠であるアセチルコリン受容体

More information

Microsoft Word - 「黄砂とその健康影響について」小冊子180323版

Microsoft Word - 「黄砂とその健康影響について」小冊子180323版 ...1...1...1...2...4...4...4...6...7...7...7...7...8...8...9...9...10... 11... 11... 11... 11...12...12...13...16...18...20 1 1-1 1-2 1 1 km 24.5 m/s 10 50 m 1 1-3 μm 1-4 1-5 2 8 http://www.jma-net.go.jp/sat/himawari/obsimg/image_dust.html

More information

L

L -G -VG -G -VG.MPa..MPa.1MPa..MPa 1.5MPa 1.5MPa 1.5MPa 1.5MPa 1 s 5 5 - -V 1.51MPa 1.5MPa s s..mpa.mpa 1.5MPa 1.5MPa - -V 1 s s 5 5 1 JISg/H 1. 1.5. 11 SLLBFFB SLLBFTC CCCCBTC..MPa 1.5MPa SLLBFFB CCCCBTC

More information

) 5 Lawton QOL 4 4 QOL Lawton 4) Philadelphia Geriatric Center Affect Rating ScaleARS ARS QOL 5) HDS R

) 5 Lawton QOL 4 4 QOL Lawton 4) Philadelphia Geriatric Center Affect Rating ScaleARS ARS QOL 5) HDS R Vol. 12 No. 2 2002 389 397 Λ1 Λ2 16 10 30 1 2 Lawton Philadelphia Geriatric Center Affect Rating ScaleARS Lawton ARS + ARS 6 2 ARS 2 12:00 15:0017:00 11:30 16:00 1 2 ARS 1 2 ARS QOL QOL QOL 1) QOL QOL

More information

untitled

untitled 5 K 5 3 HP http://www.mhlw.go.jp/bunya/shakaihosho/iryouseido01/taikou03.html 2004 1 2 1 http://www.dm-net.co.jp/calendar/2007/06/005835.php 6 85cm 100cm 2 90cm 2 TG 150mg/dl HDLHDL-C 40mg/dl 130mmHg 85mmHg

More information

2.

2. 2. 10 2. 2. 1995/12006/111995/42006/12 2. 10 1995120061119954200612 02505 025 05 025 02505 0303 02505 250100 250 200 100200 5010050 100200 100 100 50100 100200 50100 10 75100100 0250512 02505 1 025051205

More information

596_H1H4.indd

596_H1H4.indd 2014 Aug. 8No.596 http://www.saitama-ctv-kyosai.net 1021 1125 1127 10 10 27 11 11 17 11 11 20 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

More information

Microsoft Word - 表紙資料2-4

Microsoft Word - 表紙資料2-4 (1) / 130 g 25 g 520% 170 g 30 g 560% 70 mg 600 mg 11.6% 0 10.5 mg 0% (1) (2) / 50100 g 25 g 200400% 50100 g 30 g 167333% 5001000 mg 600 mg 83167% 1020 mg 10.5 mg 95190% (2) / (1) 45.6 g 30 g 152% (2)

More information

油圧1.indd

油圧1.indd 4 2 ff f f f f f f f f f f f f ff ff ff r f ff ff ff ff ff ff R R 6 7 φφ φφ φφ φ φ φφ φφφφφφφφ φφφφ φφφφ φφ! φ f f f f f f f f f f 9 f φ φ φ φ φ φ φ φ φφ φφ φ φ φ φ SD f f f KK MM S SL VD W Y KK MM S SL

More information

Ⅱ Ⅲ Ⅳ Assertive community treatment - Issues from scientific and clinical literature with implications for practice The Impact of Supported Employment and Working on Clinical and

More information

.K.C.h...C...ren

.K.C.h...C...ren 4 quality of life QOL QOL QOL 3 QOL 19 mmhg 16 mmhg 14 mmhg 1 2 7 20 30 QOL QOL QOL QOL QOL QOL QOL 4 1 1 1 2 1 2 3 1 2 4 2 2 1 2 2 2 2 1 2 3 QOL 3 2 1 1 5 1 1 2 1 Abraham Wise 1 Nd YAG 2 1 200 500 200

More information

NVA-HD1680DT

NVA-HD1680DT NVA-HD1680DT v z m qu m L L L L L t t r e w _ _ z z z z z z z zz z z z z z z z z z zz z z z z z z z z z 1 z 3 1.. 1 1 1.. 1 tc 1 J v m 1 v z z z z z z z 1 3 4 7 8 9 9 7 1 5

More information

(H8) 1,412 (H9) 40,007 (H15) 30,103 851

(H8) 1,412 (H9) 40,007 (H15) 30,103 851 (H8) 1,412 (H9) 40,007 (H15) 30,103 851 (H3) 1,466 (H3) 9,862 (H15) 4,450 704 9,795 1,677 18,488 402 44,175 3,824 8,592 853 7,635 1,695 2,202 179 5,127 841 27,631 452 35,173 177 123,797 186 45,727 1,735

More information

22 25 34 44 10 12 14 15 11 12 16 18 19 20 21 11 12 22 10 23 24 12 25 11 12 2611 27 11 28 10 12 29 10 30 10 31 32 10 11 12 33 10 11 12 34

22 25 34 44 10 12 14 15 11 12 16 18 19 20 21 11 12 22 10 23 24 12 25 11 12 2611 27 11 28 10 12 29 10 30 10 31 32 10 11 12 33 10 11 12 34 22 25 34 44 10 12 14 15 11 12 16 18 19 20 21 11 12 22 10 23 24 12 25 11 12 2611 27 11 28 10 12 29 10 30 10 31 32 10 11 12 33 10 11 12 34 35 10 12 36 10 12 37 10 38 10 11 12 39 10 11 12 40 11 12 41 10 11

More information

- 1 - - 2 - - 3 - - 4 - H19 H18-5 - H19.7H20.3 8,629 11,600-6 - - 7 - - 8 - - 9 - H20.7 20 / - 10 - - 11 - 1 8,000 16,000 4,000 2 50 12 80-12 - 20 3040 50 18a 19a - 13 - - 14 - 1,000-15 - 3,000 4,500 560

More information

17 12 12 13301515 2F1 P2 1 22 P19 160

17 12 12 13301515 2F1 P2 1 22 P19 160 136 17 12 12 13301515 2F1 P2 1 22 P19 160 161 15 87 15 P5 26 4 162 10 3 60 1/3 3 1 163 137 138 139 % %.%. (. ) ( ) 48 32 13 40 43 30 42 50 13 99 140 39 12 12 42 55 35 6 79 2004 16 17 39 37 53 13 1 1.2

More information

★索引.indb

★索引.indb S 703 S 704 S 705 S 706 S 707 S 708 S 709 S 710 S 711 S 712 S 713 S 714 S 715 S 716 S 717 S 718 20 4 15 Japanese Journal of Medical Ultrasonics 35 101 0063 2 23 1 6 F The Japan Society of Ultrasonics in

More information

3) Stedmann, E. et al.: Biochem. J., 29; 2107, 1935. 4) Reiss, M.. Hemphill, R. E. E ENature, 161 ; 18, 1948. 5) Tower, D. B. & D. MeEachern: Canada J. Reserch., 27; 105, 120, 132, 1949. 6) Wolleman, M.

More information

Special IssueDiagnoses and therapeutic agents for age-related diseases Reviews Original Case reports β Medicinal drugs affecting on clinical laboratory blood test results and adverse effects of them

More information

C-1 210C f f f f f f f f f f f f f f f f f f f f r f f f f f f f f f f f f f R R

C-1 210C f f f f f f f f f f f f f f f f f f f f r f f f f f f f f f f f f f R R 4 5 ff f f f f f f f f f f f f ff ff ff r f ff ff ff ff ff ff R R 7 b b ï φφ φφ φφ φ φ φφ φφφφφφφφ φφφφ φφφφ ù û û Æ φ ñ ó ò ô ö õ φφ! b ü ú ù û ü ß μ f f f f f f f f f f b b b z x c n 9 f φ φ φ φ φ φ

More information

油圧1.indd

油圧1.indd ff ff ff ff f f ff ff ff f f f f f f f f f f f f f f ff ff! f f f f f f f ff ff f f ff f f f f f f f f f f f f f f f f f f f f f f f f f f f f f f S 9 M6 M6 M6 M. 6 6 R/ P M. M. M. M. f f f 96 f f f M.

More information

(35H-3).pm

(35H-3).pm ff f f f f f f f f f f f f f ff ff ff f f ff ff ff f ff ff! f f f f f f f f f f f f f ff ff f f ff f f f f f f f f f f f f f f f f f f f f f S f f f f f f 9 M6 M6 M6 M. M. M. M. M. 6 6 9 R/ R/ P M. M.

More information

Synagis RS RSRespiratory Syncytial Virus RSBPD CHDRS RS RS BPD CHD 50mg100mg RS20138 RS Respiratory Syncytial Virus RS

Synagis RS RSRespiratory Syncytial Virus RSBPD CHDRS RS RS BPD CHD 50mg100mg RS20138 RS Respiratory Syncytial Virus RS RS Synagis RS RSRespiratory Syncytial Virus RSBPD CHDRS RS RS1998 7020021BPD 200510CHD 50mg100mg2012 812 RS20138 RS Respiratory Syncytial Virus RS 28 12 29 35 6 6BPD24 24CHD 24 24 28 2935 RS 12 6 RS BPD

More information

NV-DK631DT

NV-DK631DT NV-DK631DT FOR USE IN JAPAN ONLY z z z qt q w e r t t t t r e w +_ +_ z z z z z z z z z z z z z z z z z z z z L LL LL g 1 4 1.. 1 4 3 1 z z z z z z z 1 3 4 6 7 8 9 9 7 3 1 5

More information

36:378 第 38 回日本脳卒中学会講演シンポジウム 原著 36: , 要旨 TIA 2 t-pa Key words: stroke registry, stroke subtype, onset-visi

36:378 第 38 回日本脳卒中学会講演シンポジウム 原著 36: , 要旨 TIA 2 t-pa Key words: stroke registry, stroke subtype, onset-visi 36:378 第 38 回日本脳卒中学会講演シンポジウム 原著 36: 378 384, 2014 1 2 要旨 1999 2012 10 31 29 26 80 30 TIA 2 t-pa Key words: stroke registry, stroke subtype, onset-visit time, chronological change はじめに 4 12 23 27 1 Japan

More information

NV-JM525DT

NV-JM525DT NV-JM55DT z k FOR USE IN JAPAN ONLY RR6P40A45500A L LL qr q w e r z > 50 L L L L L L L L t t t r e w +_ z z z z z z z z z z z z z z z z z z z z z z z z z z z z z z z z z z z z

More information

/i 1,,._ /\YF*r$-/t, /.:/ lrfi-/l ty)t- /:V-fi-)v '+l'y)t * /;v--t:--l.'>l la- ' i>rtv /iv-i.-,v /r/tv /, / 'v1 -;l- /v F;:*#(2) A^*f *#(3) t45.5i *7v>/tvz

More information

ren

ren 51 * 1 1 IT 24 2010 NHK 2010 7.14 1960 1.08 OECD 2 5 1 2011 4 World Association of Sleep Medicine WASM 3 18 World Sleep Day 2011 11 30 no. 22730552 9 3 1 4,000 5,000 1998 4 4.4 3.3 Matsuda, 2011 Cognitive

More information

,717=Z 8,04r,s00 I 191,500 3,634,5101 slo 3oo Fl x (+E s954,\+ ElEr2s,, \) *+Errslfir+Errfrl Ir* , \v -il- )v )\2Fif- lv ./l: tt/tv^ Y7 /v7 ,7,v^,/tv YT tv^ 4a tv7 >rtv7 1D s3.so] * E r-il-2f..--_

More information

194621 22 50.06 53.96 90.00 28 87.14 85.00 80.00 75.00 70.00 22 53.96 28 80.75 65.00 60.00 55.00 22 50.06 50.00 Quality of Life !! 281026 281026 -6,500-5,500-4,500-3,500-2,500-1,500-500 500 1,500 2,500-6,401-1,281-3,565-2,154-2,265-2,027-1,869-1,657

More information

volunteer_kobe

volunteer_kobe 1 2 2 3 4 15 80 i 3 8 8 14 18 21 25 35 35 40 44 53 59 59 64 66 72 81 84 86 1 1 88 ii 90 92 94 55 96 101 102 104 106 108 110 112 113 114 115 118 120 122 124 126 130 132 133 134 135 136 138 139 140 141 145

More information

76 LOrthopédie 1a 1b ,530 3, , , / Ⅱ

76 LOrthopédie 1a 1b ,530 3, , , / Ⅱ 9275 842016 2016 1 25 4546 Ⅰ 1874 7 188720 190134 192312 193712 194924 142 1920 6 1880 5 6 1954 Orthopedic surgery 1741Nicolas Andry LOrthopédie Andrystraightfree from deformity orthoschild paidion Orthopédie

More information

1) University Group Diabetes Program: A study of hypoglycemic agents on vascular complica- in patients with adult-onset tions diabetes. I. Design, methods and baseline results. Diabetes 19 (suppl. 2):

More information

.. p.2/5

.. p.2/5 IV. p./5 .. p.2/5 .. 8 >< >: d dt y = a, y + a,2 y 2 + + a,n y n + f (t) d dt y 2 = a 2, y + a 2,2 y 2 + + a 2,n y n + f 2 (t). d dt y n = a n, y + a n,2 y 2 + + a n,n y n + f n (t) (a i,j ) p.2/5 .. 8

More information

千葉県における温泉地の地域的展開

千葉県における温泉地の地域的展開 1) 1999 11 50 1948 23) 2 2519 9 3) 2006 4) 151 47 37 1.2 l 40 3.6 15 240 21 9.2 l 7. 210 1972 5) 1.9 l 5 1 0.2 l 6 1 1972 1.9 0.4 210 40-17- 292006 34 6 l/min.42 6) 2006 1 1 2006 42 60% 5060 4050 3040

More information

がん患者の終末期ケアにおける通所リハビリテーションの役割 介護保険によるがん終末期ケアの可能性

がん患者の終末期ケアにおける通所リハビリテーションの役割 介護保険によるがん終末期ケアの可能性 2 3 3 6 7 49 53 13 61 22 27 65 68 34 47 71 73 4 5 7 6 8 9 10 11 12 13 14 15 44 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4

More information

D:/BOOK/MAIN/MAIN.DVI

D:/BOOK/MAIN/MAIN.DVI 8 2 F (s) =L f(t) F (s) =L f(t) := Z 0 f()e ;s d (2.2) s s = + j! f(t) (f(0)=0 f(0) _ = 0 d n; f(0)=dt n; =0) L dn f(t) = s n F (s) (2.3) dt n Z t L 0 f()d = F (s) (2.4) s s =s f(t) L _ f(t) Z Z ;s L f(t)

More information

x [1] Palmer Jeffrey, B. and M. Hiiemae Karen, (propulsion). (1343-8441), 1997. 1(1): p. 15-30. [2] Saitoh, E., et al., Chewing and food consistency: effects on bolus transport and swallow initiation.

More information

untitled

untitled -- -- -3- % % % 6% % % 9 66 95 96 35 9 6 6 9 9 5 77 6 6 5 3 9 5 9 9 55 6 5 9 5 59 () 3 5 6 7 5 7 5 5 6 6 7 77 69 39 3 6 3 7 % % % 6% % % (: ) 6 65 79 7 3 36 33 9 9 5 6 7 3 5 3 -- 3 5 6 76 7 77 3 9 6 5

More information